Major additional contributors were AML with KMT2A-r (n = 45) now including 19 cases (42%) with a different partner gene but MLLT3 (Supplementary Fig. S1) and AML with MECOM-r (n = 69) now including 33 cases (48%) not comprising GATA2 (Supplementary Fig. S2). The gene discussed is MLLT3; the disease is acute myeloid leukemia.